Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
Br J Cancer
; 105(12): 1811-3, 2011 Dec 06.
Article
in En
| MEDLINE
| ID: mdl-22095228
ABSTRACT
BACKGROUND:
In advanced renal cell carcinoma (RCC), sunitinib and sorafenib tyrosine kinase inhibitors (TKI) are associated with several clinical side effects, with no definitive established data concerning their clinical impact.METHODS:
From June 2006 to June 2008, main clinical TKI-induced toxicities, including digestive, cardiac, dermatologic and asthenia were retrospectively collected using the NCI-CTC version 3.0 in patients treated with TKI for an RCC.RESULTS:
The median overall survival was significantly improved in patients with grade 3-4 clinical toxicities (36 vs 12 months, P=0.009). In multivariate analysis, the Memorial Sloan-Kettering Cancer Center risk groups (good vs intermediate or poor) and clinical toxicities (grade 3-4 vs 1-2) were identified as independent prognostic factors of better survival (P=0.002 and P=0.02, respectively). The Charlson comorbidity index score (>7 vs <7) was identified as independent predictive factor of severe clinical TKI-induced toxicities (P=0.02).CONCLUSION:
In this unselected patients of RCC, clinical TKI-related severe toxicities were more frequent in patients with comorbidities and were associated with better survival.
Full text:
1
Database:
MEDLINE
Main subject:
Pyridines
/
Pyrroles
/
Benzenesulfonates
/
Carcinoma, Renal Cell
/
Protein Kinase Inhibitors
/
Indoles
/
Kidney Neoplasms
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2011
Type:
Article